Eli Lilly Discovers Dangerous Impurity in Copycat Weight-Loss Medications

Pharmaceutical giant Eli Lilly has identified a potentially harmful chemical impurity in compounded versions of its popular weight-loss drug that contain vitamin B12. The company is calling for a nationwide recall and warning consumers about unknown health risks from these unauthorized copies.

Pharmaceutical manufacturer Eli Lilly has discovered a dangerous chemical contamination in unauthorized copies of its weight-loss medication, prompting the company to issue safety warnings and demand a nationwide product recall.

In a public statement released Thursday from Washington, Lilly revealed that compounded medications combining vitamin B12 with tirzepatide – the active component in both Zepbound weight-loss treatment and Mounjaro diabetes medication – contain a harmful impurity created during manufacturing.

This announcement represents Lilly’s most recent effort to combat drug compounding facilities that the pharmaceutical company claims are producing illegal versions of its medications.

The company has initiated legal action against compounding operations, wellness facilities, and various businesses selling products that allegedly contain tirzepatide.

Compounding companies have defended their operations, claiming legal protection under specific federal regulations that permit customized drug preparation when patients need medical modifications, such as vitamin additions or dosage variations unavailable in brand-name products.

Laboratory analysis conducted by Lilly on products acquired from compounding pharmacies, medical spas, and telehealth providers revealed “significant levels of an impurity that results from a chemical reaction between tirzepatide and B12,” according to the company’s official statement and research documentation provided to Reuters.

The contamination appeared in every sample examined during Lilly’s investigation, affecting all ten products tested.

“Nothing is known about its short- or long-term effects in humans, the potential impact on the drug’s interaction with the GLP-1 and GIP receptors, toxicity, immune reactions, or how it is absorbed, distributed, metabolized, and eliminated,” the company warned in its published letter.

David Hyman, Lilly’s chief medical officer, emphasized the regulatory concerns, stating: “FDA (the U.S. Food and Drug Administration) warns that compounded products can be risky for patients because they are not reviewed for safety, effectiveness, or quality. Adding a reactive substance like vitamin B12 without clinical testing or FDA review introduces additional unknown risks.”

Lilly has informed the Food and Drug Administration about these discoveries and requested immediate recall action for all products containing both substances.

Federal regulators previously sent warning notices to 30 telehealth companies in September for making false or deceptive statements about compounded weight-loss drug alternatives.

The FDA also issued threats against “illegal copycat drugs” following telehealth provider Hims & Hers Health’s February announcement that it would begin distributing a compounded version of Novo Nordisk’s Wegovy medication.

Hims subsequently abandoned its compounded pill plans and revealed this week that it will instead offer authentic Wegovy and Ozempic products through its platform.